These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 29113955

  • 1. Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial.
    Nourbakhsh B, Revirajan N, Waubant E.
    Contemp Clin Trials; 2018 Jan; 64():67-76. PubMed ID: 29113955
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
    Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E.
    Lancet Neurol; 2021 Jan; 20(1):38-48. PubMed ID: 33242419
    [Abstract] [Full Text] [Related]

  • 3.
    Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E.
    ; 2021 06. PubMed ID: 38635797
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological treatments for fatigue associated with palliative care.
    Mücke M, Mochamat, Cuhls H, Peuckmann-Post V, Minton O, Stone P, Radbruch L.
    Cochrane Database Syst Rev; 2015 May 30; 2015(5):CD006788. PubMed ID: 26026155
    [Abstract] [Full Text] [Related]

  • 5. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
    Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L, Moreau T, Pelletier J, Lubetzki C, Clanet M, French Modafinil Study Group.
    Neurology; 2005 Apr 12; 64(7):1139-43. PubMed ID: 15824337
    [Abstract] [Full Text] [Related]

  • 6. A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: The design of the "COMBO-MS" trial.
    Kratz AL, Alschuler KN, Ehde DM, von Geldern G, Little R, Kulkarni S, Pickup K, Braley TJ.
    Contemp Clin Trials; 2019 Sep 12; 84():105821. PubMed ID: 31400515
    [Abstract] [Full Text] [Related]

  • 7. Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study.
    Ledinek AH, Sajko MC, Rot U.
    Clin Neurol Neurosurg; 2013 Dec 12; 115 Suppl 1():S86-9. PubMed ID: 24321164
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
    Yang TT, Wang L, Deng XY, Yu G.
    J Neurol Sci; 2017 Sep 15; 380():256-261. PubMed ID: 28870581
    [Abstract] [Full Text] [Related]

  • 9. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
    Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, Halper J, Johnson B, Morgante L, Grimson R.
    Neurology; 1995 Nov 15; 45(11):1956-61. PubMed ID: 7501140
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological treatments for fatigue associated with palliative care.
    Peuckmann V, Elsner F, Krumm N, Trottenberg P, Radbruch L.
    Cochrane Database Syst Rev; 2010 Nov 10; (11):CD006788. PubMed ID: 21069692
    [Abstract] [Full Text] [Related]

  • 11. Fatigue in multiple sclerosis.
    Krupp LB, Christodoulou C.
    Curr Neurol Neurosci Rep; 2001 May 10; 1(3):294-8. PubMed ID: 11898532
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial.
    Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C.
    J Neurol Sci; 2004 Mar 15; 218(1-2):103-8. PubMed ID: 14759641
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Amantadine for fatigue in multiple sclerosis.
    Taus C, Giuliani G, Pucci E, D'Amico R, Solari A.
    Cochrane Database Syst Rev; 2003 Mar 15; (2):CD002818. PubMed ID: 12804439
    [Abstract] [Full Text] [Related]

  • 16. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease.
    Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J.
    Arch Intern Med; 2001 Feb 12; 161(3):411-20. PubMed ID: 11176767
    [Abstract] [Full Text] [Related]

  • 17. Amantadine and/or transcranial magnetic stimulation for fatigue associated with multiple sclerosis (FETEM): study protocol for a phase 3 randomised, double-blind, cross-over, controlled clinical trial.
    Matias-Guiu JA, González-Rosa J, Hernández MÁ, Martínez-Ginés ML, Portolés A, Pérez-Macías N, Benito-León J, Padrón I, Prieto J, Matias-Guiu J.
    BMJ Open; 2024 Jan 04; 14(1):e078661. PubMed ID: 38176857
    [Abstract] [Full Text] [Related]

  • 18. Cognitive effects of modafinil in patients with multiple sclerosis: A clinical trial.
    Ford-Johnson L, DeLuca J, Zhang J, Elovic E, Lengenfelder J, Chiaravalloti ND.
    Rehabil Psychol; 2016 Feb 04; 61(1):82-91. PubMed ID: 26654280
    [Abstract] [Full Text] [Related]

  • 19. Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
    Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C.
    Health Technol Assess; 2000 Feb 04; 4(27):1-61. PubMed ID: 11074395
    [Abstract] [Full Text] [Related]

  • 20. 5-EPIFAT trial protocol: a multi-center, randomized, placebo-controlled trial of the efficacy of pharmacotherapy for fatigue using methylphenidate, bupropion, ginseng, and amantadine in advanced cancer patients on active treatment.
    Miladinia M, Jahangiri M, White SJ, Karimpourian H, Inno A, Chan SW, Ganji R, Maniati M, Zarea K, Ghalamkari M, Farahat A, Fagerström C.
    Trials; 2024 Apr 03; 25(1):230. PubMed ID: 38570861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.